Skip to main content
. 2024 Apr 20;16(4):564. doi: 10.3390/pharmaceutics16040564

Figure 3.

Figure 3

Individual fraction unbound vs. pralsetinib drug concentrations in subjects with normal, moderate or severe hepatic function.